Neurodegeneration – News and Features

Appoints Ronen Tamir as Executive Vice President, Marketing and Communication.

The research involves fibroblast growth factor-2 (FGF-2), a naturally occurring protein that has been studied extensively for its neuroprotective properties.

The collaboration targets a non-dopaminergic approach to treating Parkinson’s disease.

Duke researchers have found a common variation in genes puts women who are under chronic stress at risk for increased depressive symptoms, but has the exact opposite effect in men.

A group of the nation’s leaders in stem cell biology announced formation of a new biotechnology company developing drugs to control cell fate.

The Company claims that its adult stem cell therapies provide a safer approach at treating neurodegenerative diseases than competitive therapies that rely on embryonic stem cells.

The testing of PLX cells showed a reduction of TNF-a and interferon-? inflammatory cytokines that are involved in the pathogenesis of autoimmune disorders.

Results support four-fold higher arimoclomol dose for planned Phase IIb efficacy trial for ALS.

Researchers from Wisconsin and Japan had announced that they had reprogrammed adult human cells to act like embryonic stem cells.

A treatment developed at Jerusalem's Hadassah-University Hospital, still in the research stage, has been tested on 25 multiple sclerosis and ALS patients.